These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6502166)

  • 21. Phenytoin absorption in patients with ileojejunal bypass.
    Kennedy MC; Wade DN
    Br J Clin Pharmacol; 1979 May; 7(5):515-8. PubMed ID: 475946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.
    Wasserman TH; Phillips TL; Van Raalte G; Urtasun R; Partington J; Koziol D; Schwade JG; Gangji D; Strong JM
    Br J Radiol; 1980 Feb; 53(626):172-3. PubMed ID: 6245744
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy.
    Pattanaik S; Hota D; Prabhakar S; Kharbanda P; Pandhi P
    Phytother Res; 2006 Aug; 20(8):683-6. PubMed ID: 16767797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of high-dose oral and intravenous dexamethasone.
    Tóth GG; Kloosterman C; Uges DR; Jonkman MF
    Ther Drug Monit; 1999 Oct; 21(5):532-5. PubMed ID: 10519450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid infusion of phenytoin sodium loading doses.
    Salem RB; Wilder BJ; Yost RL; Doering PL; Lee C
    Am J Hosp Pharm; 1981 Mar; 38(3):354-7. PubMed ID: 7223748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral phenytoin in infancy: dose requirement, absorption, and elimination.
    Albani M; Wernicke I
    Pediatr Pharmacol (New York); 1983; 3(3-4):229-36. PubMed ID: 6677874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis.
    Workman RJ; Vaughn WK; Stone WJ
    J Clin Endocrinol Metab; 1986 Sep; 63(3):741-6. PubMed ID: 3734041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption characteristics of three phenytoin sodium products after administration of oral loading doses.
    Goff DA; Spunt AL; Jung D; Bellur SN; Fischer JH
    Clin Pharm; 1984; 3(6):634-8. PubMed ID: 6509876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenytoin intoxication during concurrent diazepam therapy.
    Rogers HJ; Haslam RA; Longstreth J; Lietman PS
    J Neurol Neurosurg Psychiatry; 1977 Sep; 40(9):890-5. PubMed ID: 599366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of prednisolone during phenytoin therapy.
    Petereit LB; Meikle AW
    Clin Pharmacol Ther; 1977 Dec; 22(6):912-6. PubMed ID: 923186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant.
    Loughnan PM; Greenwald A; Purton WW; Aranda JV; Watters G; Neims AH
    Arch Dis Child; 1977 Apr; 52(4):302-9. PubMed ID: 871217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of the bioavailability of five different phenytoin preparations.
    Hirji MR; Measuria H; Kuhn S; Mucklow JC
    J Pharm Pharmacol; 1985 Aug; 37(8):570-2. PubMed ID: 2864420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of phenytoin in the dog: a reevaluation.
    Frey HH; Löscher W
    Am J Vet Res; 1980 Oct; 41(10):1635-8. PubMed ID: 6784613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The bioavailability of phenytoin.
    Gugler R; Fröscher W; Eichelbaum M; Hildenbrand G
    J Neurol; 1977 Oct; 216(3):155-62. PubMed ID: 72133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma protein binding of phenytoin after cholecystectomy and neurosurgical operations.
    Elfström J
    Acta Neurol Scand; 1977 Jun; 55(6):455-64. PubMed ID: 878836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.
    Neuvonen PJ
    Clin Pharmacokinet; 1979; 4(2):91-103. PubMed ID: 378503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration.
    Samtani MN; Jusko WJ
    Biopharm Drug Dispos; 2005 Apr; 26(3):85-91. PubMed ID: 15654687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Protective effect of dexamethasone and phenytoin in the treatment of experimental pneumococcal meningitis].
    Martos A; Cabellos C; Martínez-Lacasa J; Viladrich PF; Gudiol F
    Enferm Infecc Microbiol Clin; 1995 Mar; 13(3):146-50. PubMed ID: 7734493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between phenytoin and cyclosporine following organ transplantation.
    Keown PA; Laupacis A; Carruthers G; Stawecki M; Koegler J; McKenzie FN; Wall W; Stiller CR
    Transplantation; 1984 Sep; 38(3):304-6. PubMed ID: 6474556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.